Research Topics
| Gregory J KatoSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Priapism in sickle-cell disease: a hematologist's perspectiveGregory J Kato
National Heart, Lung and Blood Institute, National Institutes of Health Sickle Cell Vascular Disease Section, Cardiovascular and Pulmonary Branch, Bethesda, MD 20892 1476, USA
J Sex Med 9:70-8. 2012..It also occurs in a variety of other hematological illnesses, nearly all forms of congenital hemolytic anemia, including other hemoglobinopathies and red blood cell membranopathies and enzymopathies...- Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directionsGregory J Kato
Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1476, USA
Am J Hematol 84:618-25. 2009.... - Pleiotropic effects of intravascular haemolysis on vascular homeostasisGregory J Kato
Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute and the Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1476, USA
Br J Haematol 148:690-701. 2010..This article reviews the haemolytic disorders that have been reported to manifest vascular complications, and explores the speculative possibility that haemolysis mediates some of the vascular complications of inflammation and diabetes... - Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and deathGregory J Kato
Critical Care Medicine Department, Clinical Center, NHLBI, NIH, Bethesda, MD 20892 1476, USA
Br J Haematol 145:506-13. 2009..These defects and others converge on the nitric oxide pathway in homozygous SCD with vasculopathy... - Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypesGregory J Kato
Vascular Medicine Branch, National Heart, Lung and Blood Institute, Critical Care Medicine Department, Clinical Center, National Institutes of Health, 10 Center Drive, Building 10CRC 5 5140, Bethesda, MD 20892 1476, USA
Blood Rev 21:37-47. 2007..Some of these drugs are now being studied in clinical trials... - Cerebrovascular disease associated with sickle cell pulmonary hypertensionGregory J Kato
Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1476, USA
Am J Hematol 81:503-10. 2006..Clinicians should suspect occult cerebrovascular disease in sickle cell patients with pulmonary hypertension... - Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathyGregory J Kato
Critical Care Medicine Department, Clinical Center, National Institutes of Health, 10 Center Dr, MSC 1476, Bldg 10 CRC, Room 5 5140, Bethesda, MD 20892 1476, USA
JAMA 300:2638-46. 2008..This article reviews the pathophysiology of sickle vasculopathy and the results of preliminary clinical trials of novel small-molecule therapeutics directed at abnormal vascular biology in patients with sickle cell disease... - Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell diseaseGregory J Kato
Vascular Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Dr, MSC 1476, Bldg 10CRC, Rm 5 5140, Bethesda, MD 20892, USA
Blood 107:2279-85. 2006..We propose that LDH elevation identifies patients with a syndrome of hemolysis-associated NO resistance, endothelial dysfunction, and end-organ vasculopathy... - Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortalityGregory J Kato
Vascular Therapeutics Section, Cardiovascular Branch, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA
Br J Haematol 130:943-53. 2005..Our data are consistent with steady state levels of soluble adhesion molecules as markers of pulmonary hypertension and risk of death... - Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobinJose Villagra
Vascular Medicine Branch of National Heart, Lung, and Blood Institute, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1476, USA
Blood 110:2166-72. 2007..This supports a role for NO-based therapeutics for SCD vasculopathy. This trial was registered at www.clinicaltrials.gov as no. NCT00352430... - Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell diseaseRoberto F Machado
Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1476, USA
Br J Haematol 136:319-25. 2007..001) in all subjects. These data suggest that acute elevations in pulmonary pressures during VOC or exercise may contribute to morbidity and mortality in patients with sickle cell disease... - Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell diseaseAshaunta Tumblin
Pulmonary Brance, National Heart, Lung and Blood Institute, Bethesda, MD, USA
Haematologica 95:1467-72. 2010..Acute painful episodes are the clinical hallmark of sickle cell disease and have been linked to morbidity and mortality in the sickle cell population... - Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell diseaseCaterina P Minniti
Pulmonary and Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
Br J Haematol 147:737-43. 2009..Therapy was stopped in two patients who were switched then to the other ETR blocker agent. These data suggest preliminary evidence for the benefit of bosentan and ambrisentan in pulmonary hypertension in SCD... - Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive painJames G Taylor
Pulmonary and Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS ONE 3:e2095. 2008..We have previously reported that intense hemolysis is associated with increased risk of vascular complications in a small cohort of adults with sickle cell disease. These observations have not been validated in other populations... - Increased pulmonary pressures and myocardial wall stress in children with severe malariaJacqueline J Janka
Clinical Center Critical Care Medicine Department and Pulmonary and Vascular Medicine and Translational Medicine Branches, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Infect Dis 202:791-800. 2010..To test whether this pathophysiology occurs in malaria, we examined in Mali 53 children who were admitted to the hospital with severe malaria (excluding cerebral malaria) and 31 age-matched controls... - Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertensionSuzana Zorca
Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Br J Haematol 149:436-45. 2010..05). These results characterize elevated plasma triglyceride levels as a potential risk factor for PH in SCD... - Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell diseaseJames G Taylor
Vascular Medicine Branch, NHLBI, NIH, Bethesda, Maryland 20892 1476, USA
Am J Hematol 83:6-14. 2008..Despite this protective association, patients with SC who did develop pulmonary hypertension remained at significant risk for death during 49 months of follow-up (Hazard Ratio=8.20, P=0.0057)... 
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell diseaseRoberto F Machado
Vascular Medicine Branch, Clinical Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1454, USA
JAMA 296:310-8. 2006..Levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) provide such information in patients with idiopathic pulmonary arterial hypertension...- Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemiaDeepika S Darbari
Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
J Pediatr 160:286-90. 2012.... - Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II studyA Kyle Mack
Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute National Institutes of Health, Bethesda, MD, USA
Br J Haematol 142:971-8. 2008..The unique pharmacological properties of nitrite as a hypoxia-potentiated vasodilator and cytoprotective agent in the setting of ischaemia-reperfusion injury make this anion a plausible NO donor for future clinical trials in SCD... - Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United KingdomVandana Sachdev
Cardiovascular and Pulmonary Medicine Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
Circulation 124:1452-60. 2011.... - Diet-induced weight loss in overweight or obese women and changes in high-density lipoprotein levels and functionBrittany O Aicher
Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
Obesity (Silver Spring) 20:2057-62. 2012.... - Diastolic dysfunction is an independent risk factor for death in patients with sickle cell diseaseVandana Sachdev
Cardiovascular Branch, Echocardiography Laboratory, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892 1454, USA
J Am Coll Cardiol 49:472-9. 2007..The goal of this study was to characterize left ventricular diastolic function in the sickle cell disease (SCD) population and to relate echocardiographic measures of dysfunction with pulmonary hypertension and mortality... - Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature reviewJane A Little
Vascular Medicine Branch, National Heart Lung and Blood Institute, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1476, USA
Haematologica 91:1076-83. 2006..Furthermore EPO appears to be safe in SCD, particularly when used in conjunction with HU. We outline our current therapeutic strategy for EPO use in SCD... - Infrared imaging of nitric oxide-mediated blood flow in human sickle cell diseaseAlexander M Gorbach
Infrared Imaging and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, MD, USA
Microvasc Res 84:262-9. 2012..Measurement of baseline skin temperature by IR imaging may be a useful new marker of vascular risk in adults with SCD... - Infusion of hemolyzed red blood cells within peripheral blood stem cell grafts in patients with and without sickle cell diseaseCourtney D Fitzhugh
Molecular and Clinical Hematology Branch, National Heart, Lung, and Blood Institute NHLBI National Institute of Diabetes and Digestive and Kidney Diseases NIDDK, National Institutes of Health NIH, Bethesda, MD 20892, USA
Blood 119:5671-3. 2012..Our data do not support free hemoglobin as a significant contributor to toxicity associated with PBSC infusions. This study was registered at clinicaltrials.gov (NCT00631787)... - Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell diseaseSusan Yuditskaya
Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1476, USA
Blood 113:1122-8. 2009..These results imply a relationship of apolipoproteins to the development of PAH vasculopathy in SCD, potentially involving an unexpected mechanistic parallel to atherosclerosis, another proliferative vasculopathy... - Sickle cell disease and nitric oxide: a paradigm shift?A Kyle Mack
Pediatric Oncology Branch, 10 Center Drive, MSC 1476, NCI, NIH, Bethesda, MD 20892 1476, United States
Int J Biochem Cell Biol 38:1237-43. 2006..Therapies directed at decreasing the destruction of nitric oxide, increasing the production of nitric oxide, or amplifying the nitric oxide response may prove beneficial... - Severe pulmonary hypertension in an adolescent with sickle cell diseaseJames G Taylor
Vascular Medicine Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892-1476, USA
Am J Hematol 83:71-2. 2008 - Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implicationsJonathan C Goldsmith
Blood Diseases Branch, Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 7950, USA
Am J Hematol 87:340-6. 2012..The goal of the workshop was to identify potential research questions to address knowledge gaps... - Haptoglobin halts hemoglobin's havocGregory J Kato
Sickle Cell Vascular Disease Section, Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, and Critical Care Medicine Department, Clinical Center, National Institutes of Health, Maryland 20892 1476, USA
J Clin Invest 119:2140-2. 2009..Hp prevented Hb-induced hypertension and the generation of oxidant damage to the kidney. Neutralization of free Hb appears to be part of the downstream antiinflammatory properties of glucocorticoid... - Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and managementZakari Y Aliyu
Vascular Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1662, USA
Am J Hematol 83:63-70. 2008..There is clearly a need to include Africa and other parts of the world with high SCD prevalence in future comprehensive studies on the epidemiology and treatment of end organ complications of an aging SCD population world-wide... - Sildenafil therapy in patients with sickle cell disease and pulmonary hypertensionRoberto F Machado
Vascular Therapeutics Section, Cardiovascular Branch, National Heart Lung and Blood Institute, Bethesda, MD, USA
Br J Haematol 130:445-53. 2005.... - Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in NigeriaZakari Y Aliyu
Department of Medicine and Center for Sickle Cell Disease, Howard University, Washington, District of Columbia 20060, USA
Am J Hematol 83:485-90. 2008..The inclusion of African sites in sickle cell pulmonary hypertension clinical trials should be encouraged... - Pulmonary hypertension in sickle cell disease: relevance to childrenGregory J Kato
Vascular Medicine Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
Pediatr Hematol Oncol 24:159-70. 2007..Hemolysis-associated PAH with impairments in NO bioavailability is being identified in thalassemia and other hemolytic disorders, and may be a general consequence of long-standing, severe intravascular hemolytic anemia... - Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemiaChutima Kumkhaek
Molecular and Clinical Hematology Branch, NIDDK, NIH, Bethesda, MD, USA
Br J Haematol 141:254-9. 2008..These data suggest that variation within SAR1A regulatory elements might contribute to inter-individual differences in regulation of HbF expression and patient responses to HC in SCD... - A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell diseaseNalini Raghavachari
Genomics Core Facility, Genetics and Development Biology, NHLBI, The National Institutes of Health, 10 Center Drive, Bldg 10, 8C 103B, Bethesda, MD 20892, USA
BMC Med Genomics 5:28. 2012..The field of transcriptomics is currently being revolutionized by high throughput DNA sequencing methodologies to map, characterize, and quantify the transcriptome... - High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese womenEdward Vazquez
Cardiovascular Pulmonary Branch, Proteomics Core Facility and Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
Am J Cardiol 109:527-32. 2012..This finding suggests that the functional measures of HDL might be better markers for cardiovascular risk than the HDL cholesterol levels in this population... - The proteome of sickle cell disease: insights from exploratory proteomic profilingSusan Yuditskaya
Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
Expert Rev Proteomics 7:833-48. 2010..Exploratory proteomic profiling is a valuable source of hypothesis generation for the cellular and molecular pathophysiology of sickle cell disease... - Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell diseaseClaudia R Morris
Department of Emergency Medicine, Children s Hospital and Research Center at Oakland, CA 94609, USA
JAMA 294:81-90. 2005..We hypothesized that increased arginase activity and dysregulated arginine metabolism contribute to endothelial dysfunction, pulmonary hypertension, and patient outcomes... - Current therapy of sickle cell diseaseZakari Y Aliyu
Haematologica 91:7-10. 2006 - Hemolysis-associated pulmonary hypertension in thalassemiaClaudia R Morris
Department of Emergency Medicine, Children s Hospital and Research Center at Oakland, 747 52nd Street, Oakland, California 94609, USA
Ann N Y Acad Sci 1054:481-5. 2005..Erythrocyte release of arginase during hemolysis contributes to the development of PHT. Therapies that maximize arginine and nitric oxide bioavailability may benefit patients with thalassemia... - Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell diseaseJohn J Strouse
Division of Pediatric Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Pediatr Blood Cancer 50:1006-12. 2008..We performed a retrospective cohort study to evaluate risk factors for readmission and prolonged hospitalization after different treatments for ACS... - Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!Mark T Gladwin
Haematologica 93:1-3. 2008 - A network model to predict the risk of death in sickle cell diseasePaola Sebastiani
Boston University School of Public Health, MA 02118, USA
Blood 110:2727-35. 2007..The severity score could serve as an estimate of overall disease severity in genotype-phenotype association studies, and the model provides an additional method to study the complex pathophysiology of sickle cell disease...